Medpacto said that it has signed a business agreement with HITS, specializing in artificial intelligence-based drug development.Under the accord, the two companies will jointly secure and share technology and experimental data for new drug development, establish new business models and projects for
inno. N said that the Ministry of Food and Drug Safety has approved K-CAB orally disintegrating tablet (ODT) 50mg, a gastroesophageal reflux therapy.The company plans to launch the new K-CAB formulation in the first half of this year, further spurring its share in the Korean peptic ulcer solvent mar
“In 2021, Hugel’s sales recorded 245.2 billion won ($204.4 million), the largest since the company’s foundation. In 2022, the company will go beyond the leading botulinum toxin (BTX) maker in Korea and tap the world’s three largest BTX markets – China, Europe, and the U.S.”Hugel CEO Sohn Ji-hoon sai
Handok said that it has signed a local joint promotion and sales contract with Sanofi-Aventis Korea for Renvela, the latter’s hyperphosphatemia treatment, from March.The drug is a non-calcium-based phosphorus binder that can more effectively control serum phosphorus in chronic kidney disease patient
In recent years, Korean biopharmaceutical companies have been actively licensing out drug technology in the global market. Therefore, industry watchers are now paying attention to which companies will show notable achievements this year.The domestic drugmakers showed remarkable results last year, co
CKD Bio said it obtained approval for exporting Tyemvers, a botulinum toxin (BTX) product.The company plans to ship the product to some countries that do not require a separate registration process in the Middle East and Central and South America.The Ministry of Food and Drug Safety said it granted
Samyang Biopharm USA, a global biotech subsidiary of Samyang Holdings Corp., said on Thursday that it appointed Ryu Eun-ju as its new CEO.Ryu is a new drug business strategist and marketing expert with more than 30 years of experience in global clinical trial management and drug approval, business d
Daewon Pharmaceutical said it has won approval from the Ministry of Health of the Russian Federation for Pelubi, its non-steroidal anti-inflammatory drug (NSAID), and will launch it under the brand name Pelubio.Daewon will produce Pelubi at its plant in Gyeonggi Province and export it to Russia. Pha
Institutional and individual investors' views on pharmaceutical stocks sharply divided in the first month of 2022.Stock market pharmaceutical sector index companies’ net purchase and sales in January (Unit: 100 million)According to the Korea Exchange, institutional and foreign investors’ net sellin
SK Bioscience said that it has shipped out the first 840,000 doses of Nuvaxovid, Korea's first synthetic antigen-based Covid-19 vaccine, from its plant in Andong, North Gyeongsang Province, on Wednesday.The shipment follows the Ministry of Food and Drug Safety's approval for the vaccine on Jan. 12.
Boryung Biopharma said it acquired Forbio Korea’s research unit and established a subsidiary, BPgene, to develop mRNA drugs.Forbio Korea is a developer of biological substances. Since 2014, the company has been working on new drug development using its mRNA technology.Boryung Biopharma invested in F
NeoImmuneTech said on Monday it completed the administration of NT-I7 (efineptakin alfa), a new skin cancer drug, in combination with Roche’s Tecentriq (atezolizumab) to the first patient in a phase 2 trial in the U.S.The Korean biotech company gets all doses of Tecentriq for the trial from Roche.Th
Yuhan Corp.’s non-small cell lung cancer (NSCLC) treatment Leclaza (lazertinib) is likely to score the regulatory nod soon, observers said.The Ministry of Food and Drug Safety’s central pharmaceutical affairs advisory committee recently agreed to allow Yuhan to replace a confirmatory clinical trial
Gilead Sciences’ HIV treatment and prevention drug Truvada (ingredient: emtricitabine/tenofovir disoproxil fumarate) avoided the regulator’s revocation of approval for HIV treatment.According to the minutes of the Ministry of Food and Drug Safety (MFDS)’s central pharmaceutical affairs advisory comm
The Seoul Central District Prosecutors’ Office has acquitted Daewoong Pharmaceutical of charges that the company stole Medytox’s botulinum toxin (BTX) technology.“As a result of a search and seizure, digital forensic, and statements of related employees, there is no evidence to admit that Medytox's
Daewon Pharmaceutical said it held working-level negotiations with Cigala Healthcare Group, a Saudi healthcare company, to conduct joint clinical trials for TG Fenon (Ingredient: fenofibrate), an oral Covid-19 treatment.TG Fenon is a hyperlipidemia drug that Daewon repurposed as a Covid-19 treatment
Daewoong Pharmaceutical’s subsidiary iN Therapeutics said it raised 26 billion won ($21.6 million) bridge capital for new drug development.Last year, iN Therapeutics successfully attracted 14 billion won of Series A investment.The temporary funding came from new investors, Stic Ventures and Interves
Celltrion said Monday it has confirmed the safety of its inhaled Covid-19 antibody treatment through an Australian phase 1 clinical trial and plans to start global clinical trials for a cocktail version of the inhaled treatment.Inhalon Biopharma, Celltrion's global partner, proved the inhaled antibo
Biogen’s first anti-amyloid antibody, Alzheimer’s disease treatment Aduhelm (ingredient: aducanumab), is suffering a series of setbacks.According to the annual securities filing by Biogen on Thursday, the U.S. Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) started se
Immunomic Therapeutics, a subsidiary of HLB, said it has received U.S. Food and Drug Administration’s approval to conduct the phase 1 clinical trial of ITI-3000, a Merkel cell carcinoma treatment.ITI-3000 is an anticancer vaccine made by combining LAMP1 (lysosomal-associated membrane protein) with t